Amicus Briefs

BIO submits amicus briefs on a variety of topics because of the strong interest and relevance to the biotechnology industry.

Featured Amicus Briefs
BIO Files Amicus Brief in Continuing Effort to…
BIO filed an amicus brief in a continuing effort to challenge courts' decisions that undermine FDA authority and hinder patient access to medications.The brief was filed in the Supreme Court of the United States (SCOTUS), following the August 2023…
BIO Files Amicus Brief Supporting Reversal of…
BIO filed an amicus brief in the U.S. Court of Appeals for the Sixth Circuit, seeking the reversal of a lower court's ruling that would set aside the 2022 rescission of the Securities and Exchange Commission (SEC) 2020 Rule regulating proxy advisory…
BIO Files Amicus Brief Urging Harmonization of…
BIO filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit on an important and recurring question concerning the framework for determining patent obviousness in patent litigation. BIO argues that courts, when considering whether…
All Amicus Briefs
  • Show All
Search
Results
October 16, 2020
BIO filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit on an important and recurring question concerning the framework for determining patent obviousness in patent litigation. BIO argues that courts, when considering whether…
April 22, 2019
BIO files amicus brief in support of a petition for rehearing related to patent-eligibility of diagnostic technology. 
December 28, 2018
BIO files an Amicus Brief on rehearing by the Precedential Opinion Panel of the Patent Trial and Appeal Board.
April 20, 2018
Natural Alternatives International v. Creative Compounds (BIO Brief as Amicus Curiae supporting appellant in the US Court of Appeals for the Federal Circuit)
April 9, 2018
BIO and PhRMA have submitted a brief in the U.S Court of Appeals for the Federal Circuit on behalf of appellant in Virnetx Inc. v. The Mangrove Partners. 
August 14, 2017
BIO submitted an amicus brief in the U.S. Court of Appeals for the Federal Circuit, supporting Acorda Therapeutics and reversal. 
July 14, 2017
BIO files Amicus Brief supporting rehearing en banc in Helsinn v. Teva Phamaceuticals (US Court of Appeals for the Federal Circuit)
March 17, 2017
BIO Submits Brief of Amicus Curiae in Sandoz Inc. v. Amgen Inc. v. Sandoz Inc. (Supreme Court of the United States)  
March 8, 2017
BIO and AUTM Submit Brief of Amicus Curiae in TC Heartland LLC v. Kraft Food Group Brands LLC (Supreme Court of the United States)
February 23, 2017
BIO and Croplife International Submit Brief of Amicus Curiae in Impression Products Inc. v. Lexmark International Inc. (Supreme Court of the United States)